Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie k hodnocení účinnosti a bezpečnosti/snášenlivosti subkutánního tildrakizumabu (SCH 900222/MK-3222) u účastníků se středně těžkou až těžkou chronickou plakovou psoriázou s následnou dlouhodobou prodlouženou studií (MK-3222-011) (reSURFACE 2)

3. listopadu 2026 aktualizováno: Sun Pharmaceutical Industries Limited

52týdenní, fáze 3, randomizovaná, aktivní komparátor a placebem kontrolovaná, paralelní designová studie k vyhodnocení účinnosti a bezpečnosti/snášenlivosti subkutánního tildrakizumabu (SCH 900222/MK-3222), po níž bude následovat volitelná dlouhodobá bezpečnostní rozšiřující studie , u subjektů se středně těžkou až těžkou chronickou ložiskovou psoriázou (protokol č. MK-3222-011)

This study is being conducted to evaluate the efficacy and safety/tolerability of tildrakizumab (SCH 900222/MK-3222) in a population of participants with moderate-to-severe plaque psoriasis. The primary hypotheses of the study are that tildrakizumab is superior to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of participants achieving >= Psoriasis Area Sensitivity Index of 75% (PASI-75) response and the proportion of participants with a Physician's Global Assessment (PGA) score of "clear" or "minimal" with at least a 2 grade reduction from baseline at Week 12.

Přehled studie

Detailní popis

The base study consists of a screening phase of up to 4 weeks followed by a treatment period of 52 weeks, and a 20-week follow-up period. The base study treatment period is divided into 3 sequential parts.

In Part 1 of the base study (Week 0 to Week 12), participants will be randomized to one of 4 study arms (Arm A: tildrakizumab 200 mg + matching placebo to etanercept; Arm B: tildrakizumab 100 mg + matching placebo to etanercept; Arm C: matching placebo to tildrakizumab + matching placebo to etanercept; Arm D: matching placebo to tildrakizumab + etanercept 50 mg).

In Part 2 of the base study (Week 12 to Week 28), participants in Arm A and Arm B will receive matching placebo to tildrakizumab to maintain blinding at Week 12 and will receive either tildrakizumab 200 mg (Arm A) or tildrakizumab 100 mg (Arm B) at Weeks 12 and 16. Participants in Arm A and Arm B will also receive matching placebo to etanercept once weekly through study Week 28. At study Week 12, Arm C participants will be re-randomized to receive their first dose of tildrakizumab 200 mg or tildrakizumab 100 mg, and will receive additional doses of study medication according to their re-randomized treatment assignment at Week 16. Participants in Arm C will also receive matching placebo to etanercept through treatment Week 28. Participants in Arm D will continue with once weekly doses of etanercept through study Week 28 in combination with matching placebo to tildrakizumab.

In Part 3 of the base study (Week 28 to Week 52), participants in Arm A with >= PASI-75 response at Week 28 will be re-randomized to either continue tildrakizumab 200 mg or receive tildrakizumab 100 mg at study Weeks 28, 40, and 52. Participants with >= PASI-50 response but < PASI-75 response will continue to receive tildrakizumab 200 mg every 12 weeks and those participants with < PASI-50 response will be discontinued from the study. Participants in Arm B with >= PASI-75 response at Week 28 will continue to receive tildrakizumab 100 mg every 12 weeks. Those with >= PASI-50 response but < PASI-75 response will be re-randomized to receive continued tildrakizumab 100 mg or tildrakizumab 200 mg every 12 weeks. Participants in Arm B with < PASI-50 response will be discontinued from the study. Participants in Arm C will continue to receive treatment every 12 weeks according to their re-randomized treatment assignment. Participants in Arm D that achieve >= PASI-75 response at Week 28 will be discontinued from the study. Those participants with < PASI-75 response at Week 28 will be crossed over to tildrakizumab 200 mg to receive doses at Weeks 32, 36 and 48.

Eligible participants that choose to enroll in the extension study will have an additional treatment period of up to 192 weeks and will be monitored for an additional 20 weeks in the follow-up period. Each participant will receive tildrakizumab 200 mg or tildrakizumab 100 mg every 12 weeks up to study Week 244 according to their treatment assignment at the conclusion of Part 3 of the base study.

Typ studie

Intervenční

Zápis (Aktuální)

1090

Fáze

  • Fáze 3

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to enrollment;
  • Candidate for phototherapy or systemic therapy;
  • Premenopausal female participants must agree to abstain from heterosexual activity or use a medically approved method of contraception or use appropriate effective contraception as per local regulations or guidelines
  • For the extension study: must have completed Part 3 of the base study
  • For the extension study: must have achieved at least a PASI-50 response by the end of Part 3 of the base study

Exclusion Criteria:

  • Non-plaque forms of psoriasis
  • Presence or history of severe psoriatic arthritis and is well-controlled on current treatment regimen
  • Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating
  • Participant is expected to require topical therapy, phototherapy, or systemic therapy during the trial
  • Presence of any infection or history of recurrent infection requiring treatment with systemic antibiotics
  • Previous use of entanercept, tildrakizumab (MK-3222), or other interleukin-23 (IL-23)/T- helper cell 17 (Th-17) pathway inhibitors including p40, p19, and IL-17 antagonists
  • Latex allergy or sensitivity
  • Active or untreated latent tuberculosis (TB)
  • For the extension study: women of child-bearing potential who are pregnant, intend to become pregnant within 6 months of completing the trial, or are breast feeding
  • For the extension study: active or uncontrolled significant organ dysfunction or clinically significant laboratory abnormalities
  • For the extension study: expected to require topical treatment, phototherapy, or systemic treatment during the extension study

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Tildrakizumab 200 mg

Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.

Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.

Ostatní jména:
  • SCH 900222, MK-3222

Matching placebo to etanercept administered SC

Experimentální: Tildrakizumab 100 mg

Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.

Matching placebo to etanercept administered SC

Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.

Ostatní jména:
  • SCH 900222, MK-3222
Komparátor placeba: Placebo

Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.

Matching placebo to etanercept administered SC

Matching placebo to tildrakizumab administered SC

Aktivní komparátor: Etanercept 50 mg

Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.

Matching placebo to tildrakizumab administered SC

Etanercept 50 mg administered SC

Ostatní jména:
  • Embrel

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1)
Časové okno: Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Statistical analyses presented below compare tildrakizumab to placebo to support the primary hypothesis of the study.

Week 12
Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Part 1)
Časové okno: Week 12

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Statistical analyses presented below compare tildrakizumab to placebo to support the primary hypothesis of the study.

Week 12
Percentage of Participants Experiencing an Adverse Event (AE) Up to Week 12 (Part 1)
Časové okno: Up to Week 12

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Up to Week 12
Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 12 (Part 1)
Časové okno: Up to Week 12

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Up to Week 12

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of Participants Achieving a PASI-75 Response at Week 28 (Part 2)
Časové okno: Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Primary analysis for this endpoint is for participants randomized to tildrakizumab 200 mg, tildrakizumab 100 mg, or etanercept in Part 1.

Week 28
Percentage of Participants Achieving a PASI-75 Response at Week 40 (Part 3)
Časové okno: Week 40

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants Achieving a PASI-75 Response at Week 52 (Part 3)
Časové okno: Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 28 (Part 2)
Časové okno: Week 28

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.

Week 28
Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 40 (Part 3)
Časové okno: Week 40

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 52 (Part 3)
Časové okno: Week 52

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Percentage of Participants Achieving a PASI-90 Response at Week 12 (Part 1)
Časové okno: Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline.

Week 12
Percentage of Participants Achieving a PASI-90 Response at Week 28 (Part 2)
Časové okno: Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline.

Week 28
Percentage of Participants Achieving a PASI-90 Response at Week 40 (Part 3)
Časové okno: Week 40

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants Achieving a PASI-90 Response at Week 52 (Part 3)
Časové okno: Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Percentage of Participants Achieving a PASI-100 Response at Week 12 (Part 1)
Časové okno: Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline.

Week 12
Percentage of Participants Achieving a PASI-100 Response at Week 28 (Part 2)
Časové okno: Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline.

Week 28
Percentage of Participants Achieving a PASI-100 Response at Week 40 (Part 3)
Časové okno: Week 40

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants Achieving a PASI-100 Response at Week 52 (Part 3)
Časové okno: Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Baseline Dermatology Life Quality Index (DLQI)
Časové okno: Baseline

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Baseline
Change From Baseline in the DLQI at Week 12 (Part 1)
Časové okno: Baseline and Week 12

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Baseline and Week 12
Change From Baseline in the DLQI at Week 28 (Part 2)
Časové okno: Baseline and Week 28

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Baseline and Week 28
Change From Baseline in the DLQI at Week 40 (Part 3)
Časové okno: Baseline and Week 40

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Baseline and Week 40
Change From Baseline in the DLQI at Week 52 (Part 3)
Časové okno: Baseline and Week 52

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Baseline and Week 52
Percentage of Participants With a DLQI Score of 0 or 1 at Week 12 (Part 1)
Časové okno: Week 12

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Week 12
Percentage of Participants With a DLQI Score of 0 or 1 at Week 28 (Part 2)
Časové okno: Week 28

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Week 28
Percentage of Participants With a DLQI Score of 0 or 1 at Week 40 (Part 3)
Časové okno: Week 40

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants With a DLQI Score of 0 or 1 at Week 52 (Part 3)
Časové okno: Week 52

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Mean Change From Baseline in PASI Score Over Time (Part 1)
Časové okno: Baseline and Week 4, Week 8 or Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Baseline and Week 4, Week 8 or Week 12
Mean Change From Baseline in PASI Score Over Time (Part 2)
Časové okno: Baseline and Week 16, Week 22 or Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Baseline and Week 16, Week 22 or Week 28
Mean Change From Baseline in PASI Score Over Time (Part 3)
Časové okno: Baseline and Week 32, Week 36, Week 40, Week 46 and Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Baseline and Week 32, Week 36, Week 40, Week 46 and Week 52
Mean Percent Change From Baseline in PASI Score Over Time (Part 1)
Časové okno: Baseline and Week 4, Week 8 or Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Baseline and Week 4, Week 8 or Week 12
Mean Percent Change From Baseline in PASI Score Over Time (Part 2)
Časové okno: Baseline and Week 16, Week 22 or Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Baseline and Week 16, Week 22 or Week 28
Mean Percent Change From Baseline in PASI Score Over Time (Part 3)
Časové okno: Baseline and Week 32, Week 36, Week 40, Week 46 and Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Baseline and Week 32, Week 36, Week 40, Week 46 and Week 52
Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364 and 396.

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the amount of body surface for each region involved (head=0.1; upper limbs=0.2; trunk= 0.3; and lower limbs=0.4) and the degree of involvement for each body region (0=no involvement to 6=90-100% involvement). Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-50 response indicates the number of participants achieving a 50% reduction in PASI score compared to baseline.

Week 60, 112, 172, 220, 268, 316, 364 and 396.
Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364 and 396.

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364 and 396.
Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364 and 396.

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364 and 396.
Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364
Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Week 60, 112, 172, 220, 268, 316, 364
Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Week 60, 112, 172, 220, 268, 316, 364
Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score.

PGA is assessed as: 0= Cleared, except for residual discoloration.

1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.

Week 60, 112, 172, 220, 268, 316, 364
Percentage of Subjects With a PASI75 Response Over Time (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364
Percentage of Subjects With a PASI90 Response Over Time (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364
Percentage of Subjects With a PASI100 Response Over Time (Extension Study)
Časové okno: Week 60, 112, 172, 220, 268, 316, 364

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

5. února 2013

Primární dokončení (Aktuální)

28. září 2015

Dokončení studie (Aktuální)

26. října 2021

Termíny zápisu do studia

První předloženo

13. listopadu 2012

První předloženo, které splnilo kritéria kontroly kvality

14. listopadu 2012

První zveřejněno (Odhadovaný)

20. listopadu 2012

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

5. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

3. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit